Literature DB >> 18676881

Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.

Stephan Menne1, Scott D Butler, Andrea L George, Ilia A Tochkov, Yuao Zhu, Shelly Xiong, John L Gerin, Paul J Cote, Bud C Tennant.   

Abstract

Adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) are nucleotide analogs that inhibit the replication of wild-type hepatitis B virus (HBV) and lamivudine (3TC)-resistant virus in HBV-infected patients, including those who are coinfected with human immunodeficiency virus. The combination of ADV or TDF with other nucleoside analogs is a proposed strategy for managing antiviral drug resistance during the treatment of chronic HBV infection. The antiviral effect of oral ADV or TDF, alone or in combination with 3TC or emtricitabine (FTC), against chronic woodchuck hepatitis virus (WHV) infection was evaluated in a placebo-controlled study in the woodchuck, an established and predictive model for antiviral therapy. Once-daily treatment for 48 weeks with ADV plus 3TC or TDF plus FTC significantly reduced serum WHV viremia levels from the pretreatment level by 6.2 log(10) and 6.1 log(10) genome equivalents/ml serum, respectively, followed by TDF plus 3TC (5.6 log(10) genome equivalents/ml), ADV alone (4.8 log(10) genome equivalents/ml), ADV plus FTC (one survivor) (4.4 log(10) genome equivalents/ml), TDF alone (2.9 log(10) genome equivalents/ml), 3TC alone (2.7 log(10) genome equivalents/ml), and FTC alone (2.0 log(10) genome equivalents/ml). Individual woodchucks across all treatment groups also demonstrated pronounced declines in serum WHV surface antigen, characteristically accompanied by declines in hepatic WHV replication and the hepatic expression of WHV antigens. Most woodchucks had prompt recrudescence of WHV replication after drug withdrawal, but individual woodchucks across treatment groups had sustained effects. No signs of toxicity were observed for any of the drugs or drug combinations administered. In conclusion, the oral administration of 3TC, FTC, ADV, and TDF alone and in combination was safe and effective in the woodchuck model of HBV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676881      PMCID: PMC2565907          DOI: 10.1128/AAC.00654-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  70 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

Authors:  Irene Rapti; Evangelini Dimou; Panayota Mitsoula; Stephanos J Hadziyannis
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

3.  Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.

Authors:  Chia-Yen Dai; Wan-Long Chuang; Ming-Yen Hsieh; Li-Po Lee; Jee-Fu Huang; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Jun-Fa Tsai; Wen-Yu Chang; Ming-Lung Yu
Journal:  Antiviral Res       Date:  2007-03-16       Impact factor: 5.970

4.  Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Carol A Roneker; Brent E Korba; John L Gerin; Bud C Tennant; Paul J Cote
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.

Authors:  M K Jain; L Comanor; C White; P Kipnis; C Elkin; K Leung; A Ocampo; N Attar; P Keiser; W M Lee
Journal:  J Viral Hepat       Date:  2007-03       Impact factor: 3.728

6.  Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

Authors:  Eugene Schiff; Ching-Lung Lai; Stephanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans Tillmann; Didier Samuel; Stefan Zeuzem; Jean-Pierre Villeneuve; Sarah Arterburn; Katyna Borroto-Esoda; Carol Brosgart; Steven Chuck
Journal:  Liver Transpl       Date:  2007-03       Impact factor: 5.799

7.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Authors:  R J Colonno; E V Genovesi; I Medina; L Lamb; S K Durham; M L Huang; L Corey; M Littlejohn; S Locarnini; B C Tennant; B Rose; J M Clark
Journal:  J Infect Dis       Date:  2001-10-29       Impact factor: 5.226

8.  Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.

Authors:  Huiling Yang; Christopher E Westland; William E Delaney; Elizabeth J Heathcote; Victoria Ho; John Fry; Carol Brosgart; Craig S Gibbs; Michael D Miller; Shelly Xiong
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

9.  Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.

Authors:  Kathleen M Tatti; Brent E Korba; Heather L Stang; Simon Peek; John L Gerin; Bud C Tennant; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

10.  In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.

Authors:  Xiaoping Qi; Shelly Xiong; Huiling Yang; Michael Miller; William E Delaney
Journal:  Antivir Ther       Date:  2007
View more
  20 in total

1.  Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes.

Authors:  Marta G Murreddu; Manasa Suresh; Severin O Gudima; Stephan Menne
Journal:  Methods Mol Biol       Date:  2017

2.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

3.  Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.

Authors:  Pamela A Norton; Stephan Menne; Gomathinayagam Sinnathamby; Lucy Betesh; Paul J Cote; Ramila Philip; Anand S Mehta; Bud C Tennant; Timothy M Block
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

4.  Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.

Authors:  Stephan Menne; Daniel B Tumas; Katherine H Liu; Linta Thampi; Dalal AlDeghaither; Betty H Baldwin; Christine A Bellezza; Paul J Cote; Jim Zheng; Randall Halcomb; Abigail Fosdick; Simon P Fletcher; Stephane Daffis; Li Li; Peng Yue; Grushenka H I Wolfgang; Bud C Tennant
Journal:  J Hepatol       Date:  2015-01-02       Impact factor: 25.083

Review 5.  Update on new antivirals under development for the treatment of double-stranded DNA virus infections.

Authors:  L K Dropulic; J I Cohen
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

6.  [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma.

Authors:  Nicolas Salem; Yu Kuang; David Corn; Bernadette Erokwu; Jeffrey A Kolthammer; Haibin Tian; Chunying Wu; Fangjing Wang; Yanming Wang; Zhenghong Lee
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

7.  Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.

Authors:  Pedro Berraondo; Marianna Di Scala; Kyle Korolowicz; Linta M Thampi; Itziar Otano; Lester Suarez; Jessica Fioravanti; Fernando Aranda; Nuria Ardaiz; Junming Yang; Bhaskar V Kallakury; Robin D Tucker; Marcos Vasquez; Stephan Menne; Jesús Prieto; Gloria González-Aseguinolaza
Journal:  J Hepatol       Date:  2015-03-12       Impact factor: 25.083

8.  Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma.

Authors:  Juan R Rodriguez-Madoz; Katherine H Liu; Jose I Quetglas; Marta Ruiz-Guillen; Itziar Otano; Julien Crettaz; Scott D Butler; Christine A Bellezza; Nathan L Dykes; Bud C Tennant; Jesus Prieto; Gloria González-Aseguinolaza; Cristian Smerdou; Stephan Menne
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

Review 9.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402

10.  Prevalence and epidemiological traits of HIV infections in populations with high-risk behaviours as revealed by genetic analysis of HBV.

Authors:  Y Kojima; T Kawahata; H Mori; K Furubayashi; Y Taniguchi; A Iwasa; K Taniguchi; H Kimura; J Komano
Journal:  Epidemiol Infect       Date:  2013-01-25       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.